中药治疗原发性肝癌Ⅲ期围手术期患者42例

作者	单位
陈立武	福建省第二人民医院肿瘤科福州350003
林晶	福建省第二人民医院肿瘤科福州350003
陈文	福建省第二人民医院肿瘤科福州350003
张伟平	福建省第二人民医院肿瘤科福州350003

摘要点击次数: 1379

全文下载次数: 1360

中文摘要:

目的观察中药治疗与手术相结合对原发性肝癌Ⅲ期患者的协同作用。方法综合组42例在手术前7天口服中药解毒消饮并于术后7天继续口服扶正抑瘤方2年,对照组30例只作单纯手术,比较两组手术前后细胞免疫功能、手术后的生存率及复发情况。结果综合组术后4、8周NK细胞活性及CD4+/CD8与对照组比较,差异有显著性(P<0.01)。综合组6、12、24及36个月累计生存率分别为97.6%(41/42例)、85.7%(36/42例)、52.3%(22/42例)、40.5%(17/42例),而对照组依次为96.7%(29/30例)、83.3%(25/30例)、50.0%(15/30例)、30.0%(9/30例),其中两组36个月生存率比较差异有显著性(P<0.05)。两组24个月复发率比较(综合组:54.8%,对照组:80.0%),差异有显著性(P<0.05)。结论复方中药在肝癌Ⅲ期围手术期中应用有明显作用,能够改善免疫功能、降低复发率及提高累计生存率。

英文摘要:

ObjectiveTo investigate the synergetic effect of general therapy of Chinese herbal medicine with surgical operation. Methods Fourty-two patients in the integrative group were treated with Jiedu Xiaozheng Yin for 7 days before operation, and Fuzheng Yiliu Recipe after operation for 2 years, and 30 patients in the control group underwent operation alone. Their cellular immune function, survival rate and recurrence rate were compared and analyzed. Results The accumulative survival rate of 6-month, 12-month, 24-month and 36-month in the integrative group was 97.6%(41/42), 85.7%(36/42), 52.3%(22/42) and 45.5(17/42)% respectively and those in the control group 96.7%(29/30), 83.3%(25/30), 50.0%(15/30) and 30.0%(9/30), respectively, among them the 36-month survival rate was significantly different between the two groups (P<0.05). The 24-month recurrence rate in the two groups was 54.8% and 80.0% respectively, the difference between the two was significant (P<0.05). ConclusionAdministration of compound Chinese herbal medicine in peri-operational period has definite effect on primary hepatic carcinoma in Ⅲ stage, it can improve patients’ immune function, decrease the recurrence rate and increase the cumulative survival rate.

关闭